This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

PHASE2/PHASE3UnknownINTERVENTIONAL

Enrollment

313

Participants

Timeline

Start Date

November 14, 2019

Primary Completion Date

May 22, 2022

Study Completion Date

November 22, 2022

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

AL3810

5mgQD, 7.5mgQD, 10mgQD

DRUG

carboplatin + etoposide

Carboplatin and etoposide are background treatment.

DRUG

Placebo

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai